Home
Disease Knowledge Center Drug Hub Monographs Drug Interactions Pregnancy Drug Safety Drug Recalls & Alerts OTC Navigator
Virtual Simulators Hub Clinical Cases Simulator Nutrition & Macro Calculator
Questo Insights Global Opportunities Hub AI Research Assistant Citation & Reference Generator Scholarships & Essay Planner Visa & Mobility Navigator English Assessment Test
Verified Jobs Board Pharmacy Clearance Pharmacies Directory
Practice Quizzes STEM Academy Toolkits
Medical Case Donations Opportunity Crowdfunding Community Forums Courses Academy
Back to Safety Checker

Methotrexate

Folate Antagonist Cytotoxic / Immunosuppressant

FDA Category X (Contraindicated / Fetal Risk Outweighs Any Possible Benefit) FDA Category X & Black Box Warning
Contraindicated — Black Box Fetal Demise & Teratogenicity

Methotrexate is a potent folate antagonist and abortifacient. Causes embryofetal death, spontaneous abortion, and Methotrexate/Aminopterin Syndrome (skull bone ossification defects, hypertelorism, severe growth restriction, limb malformations).

Medical Disclaimer: This report is for educational and informational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making any medication decisions during pregnancy.
Pregnancy Summary
Clinical overview for pregnancy

FDA Black Box Warning: Strictly contraindicated in pregnancy. Reliable contraception required during treatment and for at least 1 full menstrual cycle (women) or 3 months (men) post-treatment.

Trimester Safety Timeline
Safety profile across all three trimesters
1st Trimester
Weeks 1 – 12
Contraindicated

Causes embryofetal death and severe Methotrexate Embryopathy.

2nd Trimester
Weeks 13 – 27
Contraindicated

Severe fetal growth restriction, cranial bone defects, mental retardation.

3rd Trimester
Weeks 28 – Birth
Contraindicated

Fetal demise and severe bone marrow suppression.

Placental Transfer
Does this medication cross the placenta?
Crosses Placenta
Yes
Transfer Extent
High (Crosses placenta freely)

Inhibits dihydrofolate reductase (DHFR), stopping all fetal cell division.

Fetal Risk Assessment
Potential effects on the developing fetus
Methotrexate / Aminopterin Syndrome

Hypocalvaria (lack of skull bone formation), microcephaly, ocular hypertelorism, low-set ears, cleft palate, and severe limb deformities.

Maternal Risk Assessment
Potential maternal side effects during pregnancy
Hepatotoxicity & Bone Marrow Suppression

Black Box warnings for severe neutropenia, hepatotoxicity, and pulmonary toxicity.

Clinical Recommendation
Professional prescribing guidance
Strictly Contraindicated

Must not be used during pregnancy. Verify negative pregnancy test prior to initiation.

If Already Taken
"I took this before knowing I was pregnant"
1
Immediate Medical Emergency

Stop methotrexate immediately. Contact your OB/GYN and genetic counselor urgently.

Pregnancy Monitoring Protocol
Recommended follow-up and surveillance
Teratology & Ultrasound
  • Immediate teratology consultation
  • High-resolution anatomical ultrasound
Safer Alternatives
Active ingredients with better pregnancy safety profiles
sulfasalazine
Safer DMARD in pregnancy (with folic acid co-administration).
Safer DMARD
Professional Clinical Notes
Key prescribing considerations and clinical pearls
  • Black Box Warning for teratogenicity and embryofetal death.
Patient-Friendly Explanation
In simple, easy-to-understand language
Easy to Understand

Methotrexate causes fetal death and severe birth defects. It must never be taken during pregnancy.

Frequently Asked Questions
Common questions about Methotrexate in pregnancy

Women must wait at least 1 full menstrual cycle after stopping methotrexate before attempting conception. Men should wait 3 months.

Evidence Level
Quality of available safety data
FDA Category X & Black Box Warning

FDA Black Box Warning and clinical teratology database.

References & Primary Sources
Official U.S. Food & Drug Administration (FDA) PLLR & ACOG Clinical Database
All pregnancy safety evaluations, risk categories, and drug monographs are compiled directly from U.S. FDA Pregnancy and Lactation Labeling Rule (PLLR) standards and approved FDA prescribing labels.
  1. 1
    U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
  2. 2
    FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
  3. 3
    ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
  4. 4
    Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition
Search Another Medication

System Notice

Confirm Action